SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $79,982.94 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $79,982.94. Following the completion of the sale, the chief executive officer directly owned 660,391 shares in the company, valued at approximately $5,368,978.83. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, September 21st, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.33, for a total transaction of $3,515.26.

SOPHiA GENETICS Price Performance

SOPH stock opened at $7.41 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The firm has a market cap of $621.62 million, a price-to-earnings ratio of -6.44 and a beta of 0.95. The company’s fifty day simple moving average is $7.91 and its 200 day simple moving average is $6.16. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. On average, analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in SOPH. AWM Investment Company Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter worth approximately $1,772,000. Finally, 1492 Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after buying an additional 17,406 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.